- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
R2 Technology to sell ImageChecker in Japan
Mammography computer-aided detection firm R2 Technology’s ImageChecker CAD unit has received approval from the Japanese Ministry of Health and Welfare for use in breast cancer screening in Japan. The unit will be distributed by R2’s partner,
Mammography computer-aided detection firm R2 Technologys ImageChecker CAD unit has received approval from the Japanese Ministry of Health and Welfare for use in breast cancer screening in Japan. The unit will be distributed by R2s partner, Marubeni America, with which R2 signed an agreement last spring (SCAN 6/23/99).
The MHWs decision came as more good news for the Los Altos, CA, company, which is seeing its efforts to establish industry alliances pay off. In 1998, R2 signed an exclusive OEM supply deal with GE Medical Systems of Milwaukee. GE agreed to bundle ImageChecker with the full-field digital mammography system it had under development (SCAN 4/29/98). With the Food and Drug Administrations Jan. 31 approval of GEs Senographe (see story, page 5), R2 comes closer to bringing a digital version of ImageChecker to market.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
